Exelixis | EXEL - Despesa De Juros Sobre A Dívida





Despesa De Juros Sobre A Dívida Alterar Data
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Akebia Therapeutics 349.66M 12.86M 2026-06
Amgen USD 95.64B 94.98B 2026-06
AstraZeneca USD 340M 144M 2026-06
Bayer EUR 675M 87M 2025-12
BioMarin Pharmaceutical USD 63.29M 48.34M 2026-06
Bristol-Myers Squibb USD 407M 4M 2026-06
Cytokinetics USD 34.83M 1.5M 2026-06
Eisai JPY 1.96B 409M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Exelixis USD 23.4M 3.9M 2023-09
Genmab DKK 139M 129M 2026-06
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Incyte USD 582K 13K 2026-06
Ionis Pharmaceuticals USD 18M 1000K 2026-06
MacroGenics USD 4.89M 1.55M 2026-03
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Nektar Therapeutics USD 7.94M 1.83M 2026-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Pfizer USD 667M 4M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Sanofi EUR -25M 99.78M 2025-12
Takeda JPY 63.85B 20.2B 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
Xencor USD 7.35M 2.65M 2026-06